Hot Topics

FDA Approves Alecensa (alectinib) Following Tumor Resection for People with Early-Stage, ALK-Positive Non-Small Cell Lung Cancer

2024-04-19T11:06:35-05:00April 19th, 2024|Hot Topics, News, Science and Research|

Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer  On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung [...]

GO2 for Lung Cancer, Dana-Farber Cancer Institute, and Addario Lung Cancer Medical Institute Announce Expansion of Landmark Patient Research on Underlying Causes of Inherited Risk of Lung Cancer

2024-04-17T09:08:46-05:00April 17th, 2024|Hot Topics, News, Press Releases, Science and Research|

Clinical Trial Aims to Unlock the Origins of Lung Cancer   WASHINGTON and BOSTON, April 17, 2024 – In a promising step forward, GO2 for Lung Cancer (GO2), Dana-Farber Cancer Institute (Dana-Farber), and the Addario Lung Cancer Medical Institute (ALCMI), [...]

Go to Top